Month: May 2025
CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable colorectal cancer All six responders in the 20 mg/kg cohorts remain on treatment, with four patients on study for…
Read More
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at ASCO 2025. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing Oncology research and streamlining clinical trial execution for Sponsors and CROs. Meet with Christopher and Nick at this exciting event and you’ll…
Read More
One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor Excerpt from the Press Release: SAN CARLOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology…
Read More
Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are not candidates for transplant – – 89% of patients whose cancer had fully responded at the end of treatment with Columvi in combination with…
Read More
Zanzalintinib in combination with nivolumab demonstrated an objective response rate of 63% and a disease control rate of 90% – – Additional results from dose-finding cohorts will also be presented – Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–May 22, 2025– Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase…
Read More
Landmark Study from CHOP and Penn Medicine Showcases the Power of Customized Gene Editing Therapy to Treat Patient with Rare Metabolic Disease Excerpt from the Press Release: PHILADELPHIA and NEW ORLEANS, May 15, 2025 /PRNewswire/ — In a historic medical breakthrough, a child diagnosed with a rare genetic disorder has been successfully treated with a customized CRISPR…
Read More
Excerpt from the Press Release: WATERTOWN, Mass., May 15, 2025 /PRNewswire/ — Orna Therapeutics, a leading biotechnology company developing a proprietary pipeline of in vivo therapies across a broad range of autoimmune and oncology indications, today announced the presentation of new preclinical data supporting its in vivo CAR therapy approach in autoimmune diseases during an…
Read More
Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral shedding Machine learning analyses identified statistically significant correlates of protection and will be incorporated into the development of Vaxart’s second-generation norovirus vaccine candidate, which is being evaluated in a Phase 1 clinical trial Excerpt from the Press Release: SOUTH SAN FRANCISCO,…
Read More
– Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and chemotherapy – – 21% reduction in the risk of death was seen in the pre-specified subgroup of people with lymph node-positive disease – – Data to be presented as a late-breaking abstract at…
Read More
Publication follows late-breaking oral presentation of Phase 2a results at the 93rd EAS Congress; MAR001 demonstrated approximately 53% placebo-adjusted mean reductions in remnant cholesterol and triglycerides at 12 weeks Second publication of MAR001 preclinical results in eBioMedicine that demonstrate improved plasma lipid profiles Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Marea Therapeutics, Inc.,…
Read More